Elonva 150Mcg Solution For Injection is used to support pregnancy and conception through assisted reproductive technologies, and to treat hypogonadotropic hypogonadism in adolescent males.
Each Elonva injection contains 150 mcg of corifollitropin alfa, which acts similarly to follicle-stimulating hormone (FSH), one of the key reproductive hormones.
Elonva injections are used for:
Controlled ovarian stimulation in combination with GnRH antagonists, to promote the growth of multiple ovarian follicles and support the success of assisted reproduction techniques (such as IVF).
Treatment of hypogonadotropic hypogonadism in adolescent males aged 14 years and older, in combination with human chorionic gonadotropin (HCG).
The doctor determines the appropriate dose of Elonva.
The recommended dose is 100 mcg for women who weigh 60 kg or less and are 36 years old or younger.
The recommended dose is 150 mcg for women who weigh more than 60 kg, regardless of age, or for women who weigh 50 kg or more and are older than 36 years.
For males, Elonva is administered once every two weeks in the morning.
The injections are given subcutaneously (under the skin).
Elonva injections may cause some side effects, including:
Headache
Nausea
Pelvic pain
Breast pain
Fatigue
Elonva should not be used in cases of:
Hypersensitivity to any of its components
Tumors of the ovary, breast, uterus, pituitary gland, or hypothalamus
Unexplained vaginal bleeding
Primary ovarian failure
Ovarian cysts or enlargement
Uterine fibroids that may prevent pregnancy
Congenital abnormalities of the reproductive system
Risk of ovarian hyperstimulation syndrome (OHSS)
Keep out of reach of children.
Store in a refrigerator at 2–8°C.
Do not freeze.
May be stored at 25°C or below for up to one month.
Keep in the original package, protected from light.